Kat Taylor started a bank, a venture capital firm and an agribusiness to use capitalism’s toolbox to fight systemic racism, environmental destruction and economic inequality.
On March 1st, as she gathered with thousands of others to march across the Edmund Pettus Bridge in Selma, Alabama on the 55th anniversary of Bloody Sunday, Kat Taylor burst into a rendition of Aretha Franklin’s “Do Right Woman, Do Right Man.” These days, Taylor is best known as the singing spouse of billionaire climate change activist and ex-Democratic presidential candidate Tom Steyer. But in the world of impact investing, she’s famous in her own right for the breadth and ambition of her efforts, as well as her musical shtick. Indeed, Taylor’s efforts are the big reason the couple made the Forbes Impact 50 for 2020.
Way back in 2007 (the stone age in impact investing), Taylor and Steyer launched an idea they’d talked
ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced it will host an investor briefing to discuss data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The online-only event will be held following the closing of the Congress’ sessions on Saturday, September 19, 2020, beginning at 22:00 (10:00 p.m.) CEST / 4:00 p.m. EDT / 1:00 p.m. PDT.
During the briefing, Exelixis management and invited guests from the clinical community will discuss and provide context for the cabozantinib clinical data presented at the Congress. Exelixis previously announced that detailed results from CheckMate -9ER, the phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) compared with sunitinib in previously untreated patients with advanced or metastatic renal cell carcinoma, will be presented during the Congress’ Presidential Symposium I earlier in the day. The investor briefing will also review data from COSMIC-021, the